158 related articles for article (PubMed ID: 35046801)
1. Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance.
Cui Q; Hu Y; Cui Q; Wu D; Mao Y; Ma D; Liu H
Front Pharmacol; 2021; 12():746707. PubMed ID: 35046801
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
[No Abstract] [Full Text] [Related]
3. Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis.
Zeng X; Wan X; Xu J; Wang H; Chen H; Zeng Q; Zhang W; Zhao B
Aging (Albany NY); 2020 Apr; 12(8):7129-7162. PubMed ID: 32324592
[TBL] [Abstract][Full Text] [Related]
4. Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis.
Zhou G; Guo L; Xu J; Tang K; Chen J
Ther Adv Med Oncol; 2024; 16():17588359241227677. PubMed ID: 38304850
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Chen RL; Chen HJ; Jiang BY; Zhang XC; Zhou Q; Tu HY; Zhong WZ; Wu YL; Yang JJ
Clin Transl Oncol; 2018 Feb; 20(2):243-252. PubMed ID: 28702789
[TBL] [Abstract][Full Text] [Related]
6. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
White MN; Piper-Vallillo AJ; Gardner RM; Cunanan K; Neal JW; Das M; Padda SK; Ramchandran K; Chen TT; Sequist LV; Piotrowska Z; Wakelee HA
Clin Lung Cancer; 2022 May; 23(3):e210-e221. PubMed ID: 34887193
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
Saw SPL; Low YF; Lai GGY; Chan LL; Wong WKY; Tsui G; Chen OH; Seet AOL; Tan WC; Tan AC; Chan JWK; Teh YL; Tan WL; Ng QS; Ang MK; Kanesvaran R; Lim DWT; Tan DSW; Mok TSK; Li MSC
Lung Cancer; 2024 Jun; 193():107856. PubMed ID: 38889498
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
10. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
[TBL] [Abstract][Full Text] [Related]
11. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
[TBL] [Abstract][Full Text] [Related]
12. Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial.
Kobayashi N; Hashimoto H; Kamimaki C; Nagasawa R; Tanaka K; Kubo S; Katakura S; Chen H; Hirama N; Ushio R; Aoki A; Nakashima K; Teranishi S; Manabe S; Watanabe H; Horita N; Watanabe K; Hara Y; Yamamoto M; Kudo M; Piao H; Kaneko T
Thorac Cancer; 2020 Aug; 11(8):2125-2129. PubMed ID: 32495514
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.
Zhang Y; Zeng L; Zhang X; Li Y; Liu L; Xu Q; Yang H; Jiang W; Lizaso A; Qiu L; Hou T; Liu J; Peng L; Yang N
BMC Med; 2021 Oct; 19(1):245. PubMed ID: 34663309
[TBL] [Abstract][Full Text] [Related]
14. Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients.
Chen Y; Jiang N; Liang X; Chen N; Chen Y; Zhang C; Shi J; Guo R
Oncol Lett; 2023 Aug; 26(2):323. PubMed ID: 37415629
[TBL] [Abstract][Full Text] [Related]
15. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.
Wang K; Du R; Roy-Chowdhuri S; Li ZT; Hong L; Vokes N; Elamin YY; Hume CB; Skoulidis F; Gay CM; Blumenschein G; Fossella FV; Tsao A; Zhang J; Karachaliou N; O'Brate A; Gann CN; Lewis J; Rinsurongkawong W; Lee JJ; Gibbons DL; Vaporciyan AA; Heymach JV; Altan M; Le X
JTO Clin Res Rep; 2023 Aug; 4(8):100533. PubMed ID: 37649681
[TBL] [Abstract][Full Text] [Related]
16. ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in
Lee JB; Ou SI
Lung Cancer (Auckl); 2024; 15():81-85. PubMed ID: 38818015
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.
Feng PH; Chen KY; Huang YC; Luo CS; Wu SM; Chen TT; Lee CN; Yeh CT; Chuang HC; Han CL; Lin CF; Lee WH; Kuo CH; Lee KY
J Thorac Oncol; 2018 Jul; 13(7):958-967. PubMed ID: 29684573
[TBL] [Abstract][Full Text] [Related]
18. Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.
Aredo JV; Wakelee HA; Neal JW; Padda SK
Cancer Treat Res Commun; 2022; 30():100497. PubMed ID: 34920242
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib.
Kaira K; Imai H; Mouri A; Hashimoto K; Miura Y; Shiono A; Yamaguchi O; Kobayashi K; Kawasaki T; Yasuda M; Kagamu H
Thorac Cancer; 2023 Oct; 14(29):2950-2961. PubMed ID: 37605832
[TBL] [Abstract][Full Text] [Related]
20. Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.
Hakozaki T; Okuma Y; Hashimoto K; Hosomi Y
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2555-2564. PubMed ID: 31350622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
